To create its new drugs, Afecta uses a suite of proprietary technologies for pharmacogenetic analysis, chemo-genomic based molecular modeling and bio-informational processing. These enable the rational identification of existing compounds which can be re-directed, re-engineered or re-formulated, based on the molecular biological and genetic characteristics of the target disease or population to be treated.

Afecta uses proprietary pharmacogenetic profiling technology combined with in vivo and in vitro response indicator platforms to study genes and genetic expression patterns obtained from clinical samples and/or non-human or cellular models of our target diseases. This data allows the therapeutic subtyping of complex diseases, as well as the identification of better drugs targets, and clinical response markers. Facilitating this process is our extensive bank of clinical samples related to the target disorders.

Afecta also employs a proprietary in silico structure-activity enhancement process. This is used to design novel variations or derivatives of a prototype drug that have improved performance characteristics. This results in the creation of relatively small collections of late stage "high value" pre-clinical compounds that can be tested on a narrow set of pre-defined functionality assays. Using reiterative selection and statistical modeling, the precise molecular features of the ideal candidate drugs are matched to molecular targets.

For clinical testing of new drugs we have developed a unique computer-based database process and analytic system that employs principal component analysis and path analysis to facilitate the integration and evaluation of disparate data sets. From this we can model more efficient clinical studies, optimize data analysis and collect data electronically through web-based portals.